Skip to main content
. Author manuscript; available in PMC: 2009 Jun 9.
Published in final edited form as: J Neurochem. 2008 Apr 10;106(2):591–602. doi: 10.1111/j.1471-4159.2008.05409.x

Fig. 6. MEK1/2 inhibitor U0126 attenuates 4HPR-induced AP-1 transactivation.

Fig. 6

ARPE-19 cells in culture were pretreated with 1 μM of U0126 for 1 h followed by incubation with 1 μM 4HPR for additional 72 h. Nuclear extracts prepared were used for analyzing the AP-1 transcription factor activation by quantitative ELISA using antibodies specific for the activated form of c-Fos or phosphorylated c-Jun as described under Materials and Methods. The specificity of AP-1 activation was verified using wild type oligonucleotide (4HPR-WT) or mutated oligonucleotide (4HPR-MO). Panel A, c-Jun mediates 4HPR-induced transactivation of AP-1. Panel B, c-Fos mediates 4HPR-induced transactivation of AP-1. The values are mean ± SD, n = 4. *P < 0.01 compared to control; **P <0.001 compared with 4HPR treatment.